Astria Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corpo

-- On Track to File IND Application for STAR-0215 Mid-Year ---- Initial Phase 1a Clinical Results Anticipated by Year End 2022 --BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies fo...

Related Keywords

United States ,American ,Jillc Milne ,Instagram Astriatx ,Andrea Matthews ,Quellis Biosciences ,Linkedin ,Neither The Company ,Twitter ,Facebook ,Astria Therapeutics Inc ,Nasdaq ,American Academy Of Allergy ,Clinical Results Anticipated ,Year End ,Astria Therapeutics ,Chief Executive Officer ,Investigational New Drug ,American Academy ,Immunology Annual Scientific Meeting ,Full Year ,Loss Per Share Basic ,Annual Report ,Ended December ,Consolidated Statements ,Cash Flows ,